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REVIEW
Abstract: The pathophysiology of obsessive-compulsive disorder (OCD) remains unknown.
However, increasing attention has been paid to the putative role of the serotoninergic system,
the strongest evidence being based on the widely demonstrated efficacy of serotonin (5HT)
reuptake inhibitor antidepressants in the treatment of OCD. The therapeutic effects are
correlated with changes in peripheral parameters of 5HT function, which have been found to
be altered in OCD, suggesting the possibility of reduced 5HT reuptake capacity. This could
reflect a compensatory mechanism presumably due to decreased availability of extracellular
5HT, as evidenced by data derived from direct assessment of central 5HT neurotransmission.
The development of new neurochemical probes that explore the sensitivity of various 5HT
receptor subtypes has provided precious information. m-Chlorophenylpyperazine (m-CPP),
an agonist to 5HT1A, 5HT1D, and 5HT2C receptors, and which also blocks 5HT3 receptors,
exacerbates OC symptoms. In contrast, neither MK-212 (6-chloro-2-[1-piperazinyl]-pyrazine),
a 5HT1A and 5HT2C receptor agonist, nor ipsapirone or buspirone, which acts as an agonist
to 5HT1A receptors, have any effect on OC symptom severity. This suggests the potential
implication of the 5HT1D receptor, as shown by the aggravation of OC manifestations in
response to sumatriptan, a selective 5HT1D receptor agonist. The 5HT3 plays no specific
role, given the lack of influence of the 5HT3 antagonist ondansetron, on OC symptom intensity.
Further studies are required to elucidate the pharmacological molecular determinants of the
putative 5HT1D receptor dysfunction.
Keywords: serotonin, serotonin reuptake inhibitors, receptors, serotonin, 5HT1D receptor
agonists, obsessive-compulsive disorder
Introduction
Obsessive-compulsive disorder (OCD) is a relatively common anxiety disorder
characterized by recurrent intrusive thoughts and repetitive time-consuming behaviors,
with an estimated lifetime prevalence of 2%–3% in the general population (Antony
et al 1998). OCD generally has a chronic course and causes severe distress with a
significant impairment in quality of life and social and occupational functioning
(Koran et al 1996). To date, the pathophysiology of OCD remains unclear. However,
during the last decade, an increasing interest among researchers has contributed to
the putative involvement of the serotoninergic function. This assumption primarily
stems from indirect arguments based on the well established efficacy of the
antidepressant agents with serotonin (5HT) reuptake inhibiting properties for treating
OCD (Flament and Bisserbe 1997; Goodman 1999; McDougle 1999; Pigott and
Seay 1999).
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After general considerations about the anatomical and
functional organization of the 5HT system, the present
review examines the putative role of 5HT neurotransmission
in OCD through separate and complementary approaches
that can be summarized as follows: (1) evaluation of 5HT
function in response to drug treatment with a view to
establishing strong relationships between the anti-
obsessional effects of antidepressant agents acting
preferentially by blocking 5HT reuptake process and their
influence on peripheral markers of 5HT function;
(2) assessment of 5HT function based on direct measure-
ments of some peripheral and central parameters; and
(3) exploration of 5HT function with diverse pharmaco-
logical challenges for studying a relatively large variety of
5HT receptor subtypes and their importance in the
production of OC symptoms. Thereafter, 5HT disruption is
discussed within the context of a complex anatomo-
functional model for OCD emerging from phenomeno-
logical aspects. Finally, possible interactions with other
neurotransmitter systems, particularly dopamine, are
discussed.
General anatomical and functional
characteristics of 5HT system
The 5HT-producing neurons are mainly located in the
brainstem raphe nuclei that are described as giving rise to
two major groups of neurons: (1) the superior group at the
interface between the midbrain and the pons; and (2) the
inferior group located more caudally in the pons (Azmitia
and Whitaker-Azmitia 1995). They form the largest and most
complex neurochemical efferent system in the brain. The
superior group of 5HT neurons comprising the dorsal and
median raphe nuclei is the source of vast projections to
various sites in the forebrain. Rich 5HT innervations of
telencephalic limbic regions such as the prefrontal and
cingulate cortices, the amygdala, hippocampus, and ventral
striatum, and diencephalic structures, especially the
hypothalamus and thalamus, are found (Bentivoglio et al
1993; Azmitia and Whitaker-Azmitia 1995; Murphy et al
1998; Stahl 1998; Deutch and Roth 1999) (Figure 1). The
dorsal and median raphe nuclei differentially innervate the
forebrain target regions. For instance, the dorsal raphe
nucleus provides projections primarily to the amygdala and
Figure 1 Schematic representation of the serotoninergic projections from the brainstem raphe nuclei to the forebrain and relationship with the cortico-subcortical
loops. The cell bodies of the serotoninergic neurons are present in the brainstem raphe nuclei. They provide important innervations to a wide range of limbic target
regions in the forebrain, comprising the orbital prefrontal and anterior cingulate cortices, ventral striatum, and thalamus belonging to the orbitofrontal and anterior
cingulate loops, and other related structures, especially the amygdala, hippocampus, and hypothalamus.
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ventral striatum, whereas the median raphe nucleus
preferentially innervates the prefrontal and cingulate cortices
and the hippocampus. The lowest levels of 5HT fibers are
seen in the motor regions of the frontal lobe (Azmitia and
Whitaker-Azmitia 1995). The inferior group of 5HT-
containing neurons sends abundant descending spinal
projections (Azmitia and Whitaker-Azmitia 1995; Deutch
and Roth 1999).
The 5HT is formed via a two-step pathway following
the initial active uptake of the essential amino acid precursor
tryptophan into the neuron (Deutch and Roth 1999; Sanders-
Bush and Mayer 2001). The first step of this synthesis
involves the enzyme tryptophan hydroxylase that converts
tryptophan to 5-hydroxytryptophan, the intermediate
precursor of 5HT. The brain tryptophan hydroxylase is not
saturated with substrate. This is very important for
explaining the influence of the levels of tryptophan in
dietary sources (and thus in brain) on 5HT synthesis (Barr
et al 1992; Deutch and Roth 1999; Sanders-Bush and
Mayer 2001). The second step is the decarboxylation of
5-hydroxytryptophan in 5HT by the enzyme L-amino acid
decarboxylase, which also participates in catecholamine
synthesis. 5HT is stored in the vesicles before their fusion
to the neuronal membrane and is then released into the
synaptic cleft, a process called exocytosis, in a Ca
2+-
dependent manner in response to depolarizing stimuli. The
5HT actions are mainly terminated by reuptake into
presynaptic neurons through 5HT transporter proteins
present in the outer membrane of the axon terminals (Deutch
and Roth 1999; Sanders-Bush and Mayer 2001). The 5HT
transporter surface expression is controlled through
kinase-linked pathways particularly involving protein
kinase C (PKC) (Qian et al 1997; Blakely et al 1998;
Ramamoorthy et al 1998; Ramamoorthy and Blakely 1999).
Autoradiographic studies using antidepressant drugs with
potent inhibitor profiles for 5HT transporter as radioactive
ligands have found high densities of 5HT uptake sites in
the brain regions receiving large inputs from the raphe nuclei,
including the prefrontal cortex, amygdala, hippocampus,
ventral striatum, hypothalamus, and thalamus (Bentivoglio
et al 1993; Barker and Blakely 1995; Meneses 1999). The
5HT uptake system has also been identified in a number of
specialized non-neuronal cells, especially in platelet and
lymphocyte membranes taking up 5HT from the blood,
thereby keeping the 5HT levels in blood low (Barker and
Blakely 1995; Sanders-Bush and Mayer 2001). In addition,
a metabolic degradation of 5HT occurs primarily involving
the enzyme monoamine oxidase type A (MAO-A) present
on the outer surface of mitochondria, which metabolizes
5HT to form 5-hydroxyindole acetaldehyde. This aldehyde
is then converted to 5-hydroxyindole acetic acid (5-HIAA)
by the ubiquitous mitochondrial enzyme aldehyde
dehydrogenase (Sanders-Bush and Mayer 2001).
The current, widely accepted classification proposes at
least seven distinct recognition sites for 5HT (Sanders-Bush
and Canton 1995; Murphy et al 1998; Stahl 1998; Sanders-
Bush and Mayer 2001). All members of the 5HT1 receptor
subtype belong to the superfamily of G protein-coupled
receptors. They generally inhibit adenylate cyclase, leading
to decreased cyclic adenosine monophosphate (cAMP)
production. The 5TH1A receptor represents a somato-
dendritic autoreceptor on the cell body of 5HT neurons in
the brainstem raphe nuclei. Another subtype, the 5HT1B
receptor (and its human homolog, 5HT1D) has been found
to function as an autoreceptor on axon terminals. When
activated, these two receptors decrease the intrinsic firing
of the raphe cells, thereby inhibiting 5HT release. The
5HT1A receptors have also been characterized at post-
synaptic sites. A significant amount of 5HT1B receptors
are present on postsynaptic structures, yet their function is
still unknown (Sanders-Bush and Canton 1995; Murphy et
al 1998; Marek and Aghajanian 1999; Sanders-Bush and
Mayer 2001). The 5HT1 receptor subtypes are mainly
located in the brainstem raphe nuclei and various cortical
and subcortical limbic target regions (Boschert et al 1994;
Glennon and Dukat 1995; Stahl 1998; Meneses 1999). The
so-called 5HT2 receptor family comprises characterized
receptors that have been referred to as 5HT2A and 5HT2C
receptors coupled to G proteins. They are associated
primarily with phospholipase C that catalyzes the hydrolysis
of phosphatidylinositol bisphosphate (PIP2) and generates
the second messenger molecules inositol triphosphate (IP3)
(which mobilizes calcium from intracellular stores resulting
in PKC activation) and diacylglycerol (which potentiates
PKC activation). PKC regulates numerous processes of cell
function. For example, PKC activation causes a reduction
in 5HT uptake capacity by phosphorylation and
sequestration of 5HT transporter proteins (Qian et al 1997;
Blakely et al 1998; Ramamoorthy et al 1998; Ramamoorthy
and Blakely 1999). The 5HT2 receptor subcategories have
a widespread distribution in the brain (Glennon and Dukat
1995; Meneses 1999; Sanders-Bush and Mayer 2001). The
5HT3 receptors are members of the large family of ligand-
operating ion channels that regulate the permeability of
cation channels. They are primarily located on nerve
terminals, where they facilitate 5HT release (Sanders-BushNeuropsychiatric Disease and Treatment 2005:1(3) 234
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and Canton 1995; Murphy et al 1998; Marek and Aghajanian
1999; Sanders-Bush and Mayer 2001). In the central nervous
system, these receptors are present in the prefrontal and
entorhinal cortices, the amygdala and hippocampus, or in
the area postrema. They have also been identified in the
gastrointestinal tract, so they are involved in the emetic
response (Glennon and Dukat 1995; Stahl 1998; Meneses
1999; Sanders-Bush and Mayer 2001). Four additional
5HT receptor subcategories have more recently been
characterized (5HT4, 5HT5, 5HT6, and 5HT7). Although
little is still known about the pharmacology and functional
role of these receptors, most are coupled to G proteins and
stimulate adenylate cyclase, resulting in cAMP accumulation
and activation of protein kinase A (PKA) (Sanders-Bush
and Canton 1995; Murphy et al 1998; Sanders-Bush and
Mayer 2001). However, unlike PKC, PKA-triggered
phosphorylation seems to have no modulating effect on 5HT
transporter function (Blakely et al 1998).
The 5HT system has been widely demonstrated to be
involved in the pathogenesis of diverse mental illnesses such
as OCD. Several lines of evidence suggest that the
dysfunction of 5HT neurotransmission, and especially an
altered sensitivity of the 5HT receptor subtype, may
constitute a crucial factor in the pathophysiology of OCD.
Drug treatment responses
The strongest evidence for the putative role of the 5HT
system is provided by the increasing number of clinical
studies pointing to the efficacy of 5HT reuptake inhibitor
antidepressants (SRIs) for the pharmacological treatment
of OCD. The earlier investigations were performed with the
tricyclic antidepressant clomipramine, which has a
preferential serotoninergic profile. It has extensively been
shown that clomipramine consistently reduces OC
symptomatology (Flament and Bisserbe 1997; Goodman
1999; McDougle 1999; Pigott and Seay 1999). A positive
correlation has been found between plasma clomipramine
levels and the anti-obsessional response (Stern et al 1980;
Mavissakalian et al 1990). In contrast, plasma levels of its
major metabolite N-desmethylclomipramine, which exerts
a potent blockade of norepinephrine reuptake, were not
related to the clinical outcome (Stern et al 1980;
Mavissakalian et al 1990). Many studies have also
documented the importance of non-tricyclic selective 5HT
reuptake inhibitors (fluvoxamine, fluoxetine, paroxetine,
sertraline, and citalopram) as anti-obsessional medications
(Flament and Bisserbe 1997; Goodman 1999; McDougle
1999; Pigott and Seay 1999). The efficacy of these agents
contrasts with the lack of therapeutic effects of anti-
depressants such as desipramine, which has a preponderant
blocking action on norepinephrine reuptake (Ananth et al
1981; Volavka et al 1985; Goodman et al 1990; Hoehn-Saric
et al 2000).
The central role of 5HT neurotransmission is illustrated
by the change in peripheral markers of 5HT function
associated with the improvement in OCD symptoms after
treatment with SRIs.
In the early study by Flament et al (1987), platelet 5HT
contents in OCD patients exhibited a profound decrease after
a five-week period of treatment with clomipramine, which
was positively correlated with the clinical improvement.
However, a lesser reduction in 5HT content in whole blood
after one week of treatment with paroxetine or clomipramine
was more recently found to be associated with a better anti-
obsessional response at 12 weeks (Humble et al 2001).
Treatment with clomipramine for three weeks was also
reported to reduce the concentrations of 5-HIAA, the major
central metabolite of 5HT, in the lumbar cerebrospinal fluid
(CSF) (as a measure of central 5HT turnover) of OCD
patients. This progressive decline in CSF levels of 5-HIAA
was positively correlated with an alleviation in OCD
symptoms (Thoren et al 1980). Similar results were found
in OCD children and adolescents treated with clomipramine
over a longer period of time ranging from 8.5 to 34 months
(Altemus et al 1994). These findings support the correlation
found between the decrease in CSF 5-HIAA levels and the
5HT reuptake inhibiting activity determined in vitro in
plasma of depressed patients receiving clomipramine
(Asberg et al 1977). Thus, it can be postulated that an
enhanced availability of 5HT at the synapse, due to
presynaptic reuptake inhibition, may be a central factor in
the clinical efficacy of antidepressant agents in OCD.
Such a phenomenon might lead to a variety of adaptive
changes in 5HT transporter function, as suggested by a
gradual elevation of the number of 3H-imipramine binding
sites labeling the 5HT transporter in blood platelets until
normalization after an eight-week trial with either
fluvoxamine or clomipramine. This was paralleled by an
improvement in OC manifestations (Marazziti et al 1997).
An enhanced 5HT reuptake rate with a decrease in the
inhibitory effect of PKC occurred after six months of
treatment of OCD with various SRIs (Marazziti et al 2002).
This could be a possible consequence of a reduction in the
platelet levels of IP3, an intracellular product of the 5HT2
receptor-mediated phosphoinositide hydrolysis stimulating
PKC, before returning to normal values after an eight-weekNeuropsychiatric Disease and Treatment 2005:1(3) 235
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SRI treatment (Delorme et al 2004). This decrease in the
platelet IP3 content was positively correlated with a
reduction in the number of 5HT2A receptor binding sites
(Delorme et al 2004), which could be reflective of
postsynaptic receptor down-regulation caused by SRI
administration (Maes and Meltzer 1995; Duman 1999).
Consequently, these data suggest that 5HT function
appears to mediate the reducing action of SRI medications
on OC symptoms. They raise the essential question of
putative disturbances in the availability of extracellular 5HT
in OCD, which might affect: (1) presynaptic release
regulated by 5HT autoreceptors; (2) reuptake into nerve
terminals; and/or (3) metabolic inactivation, before being
reversed during successful treatments with SRIs.
Peripheral and central markers
Over the last decade, a growing body of literature has
explored the functioning of the 5HT system in OCD. Some
studies have shown abnormalities of several markers,
thereby reflecting the functional activity of 5HT
neurotransmission.
Although no change was found in platelet (Flament et
al 1987), whole blood (Hanna et al 1991; Delorme et al
2004), 5HT content, or in platelet MAO activity (Flament
et al 1987), enhancement of CSF levels of 5-HIAA, possibly
reflecting increased brain 5HT turnover, was observed in
OCD patients (Insel et al 1985). However, these results have
not been confirmed in other investigations that reported
normal CSF concentrations of 5-HIAA (Thoren et al 1980;
Leckman et al 1995). A positive correlation was found
between the CSF levels of 5-HIAA in children with primary
OCD and only one of the eight baseline measures of clinical
symptom severity (NIMH Global OCD scale score), and
the three Leyton Obsessional Inventory-Child Version
improvement scores after five weeks of treatment with
clomipramine (Swedo et al 1992). Therefore, these reports
fail to establish any clear association between 5HT turnover
characteristics and OC symptoms.
Many investigations have documented an alteration of
the 5HT reuptake process in OCD, as shown by
modifications of three distinct parameters of the 5HT
transporter protein function, ie, number, affinity, and
velocity. Most of the studies to date have used 3H-
imipramine or the more selective ligand 3H-paroxetine as
an index of the 5HT reuptake sites in platelets or
lymphocytes. A reduction in 3H-impramine binding was
found in OCD patients (Weizman et al 1986). Several
research groups confirmed these results by finding fewer
platelet or lymphocyte 3H-impramine or 3H-paroxetine
binding sites in OCD (Bastani et al 1991; Marazziti et al
1992, 1996, 2003; Sallee et al 1996; Delorme et al 2004).
Nevertheless, others failed to replicate these findings and
reported a normal density in platelet 5HT transporter (Insel
et al 1985; Black et al 1990; Kim et al 1991; Vitiello et al
1991). A decreased affinity for 5HT reuptake was found
(Bastani et al 1991). Although normal (Weizman et al 1986;
Bastani et al 1991; Marazziti et al 1992) or increased velocity
of 5HT uptake has been observed (Vitiello et al 1991), a
lower 5HT reuptake velocity at baseline and in response to
PKC activation in platelets of OCD patients was recently
found compared with normal controls (Marazziti et al 2000).
This is consistent with the inhibitory effects of PKC leading
to the internalization of 5HT transporter and loss of
functional transport capacity (Qian et al 1997; Blakely et al
1998; Ramamoorthy et al 1998; Ramamoorthy and Blakely
1999), and suggests an elevated PKC activity in OCD. These
findings strictly parallel those by Delorme et al (2004)
showing a disturbance in the second messenger pathway
coupled to 5HT2 receptors with enhanced IP3 con-
centrations in the platelets of OCD patients. This might
increase the release of calcium from internal storage sites
and therefore PKC activity. Abnormalities in the PKA have
also been reported with decreased c-AMP-stimulated PKA
activity (Perez et al 2000) and a reduced phosphorylation
state of the PKA substrate Rap1 (Tardito et al 2001) in the
platelets of OCD patients. However, changes in PKA activity
and 5HT uptake kinetic have still not been demonstrated to
be linked. On the other hand, although no correlation was
found between platelet 3H-impramine binding site density
and clinical measures of symptom severity (Black et al
1990), the number of 3H-paroxetine sites was negatively
correlated with OC symptom intensity (Marazziti et al 1996).
Therefore, these observations are, in general, suggestive of
relationships between decreased capacity of presynaptic
5HT reuptake and OC manifestations.
5HT transporter dysfunction appears to occur in platelets,
which have become the most widely used peripheral index
of the central 5HT system. However, this raises the crucial
question of whether such abnormalities are also present in
the central 5HT system. For this reason, brain 5HT
transporter availability has recently been investigated in
OCD patients using functional neuroimaging techniques. It
has been shown that 5HT transporter availability is increased
in the midbrain-pons. This could result from a decreased
competition by lower endogenous 5HT levels leading to a
greater number of available reuptake binding sites (PogarellNeuropsychiatric Disease and Treatment 2005:1(3) 236
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et al 2003). In contrast, there was normal 5HT transporter
availability in the limbic and subcortical regions, including
the anterior cingulate cortex, hippocampus, amygdala,
ventral striatum, and thalamus (Simpson et al 2003).
To summarize, indirect evidence for the involvement of
the 5HT system has emerged from numerous pharmaco-
logical studies showing the therapeutic effects of SRIs in
OCD, which thus appear to be associated with changes in
peripheral indices of 5HT function. Direct analysis of
peripheral and central markers of 5HT neurotransmission
suggests that OCD could be associated with decreased
availability of extracellular 5HT. This hypothesis leads to
the consideration that specific abnormalities of 5HT release
and/or 5HT receptors could exist in OCD. From this
perspective, a reduction in 5HT reuptake capacity could be
considered as a compensatory mechanism in the attempt to
maintain the availability of extracellular 5HT.
Pharmacological challenges
Another powerful technique for evaluating the role of 5HT
in OCD is investigating whether pharmacological challenges
acting on 5HT receptors or 5HT subsystems exacerbate or
improve the symptoms of OCD. Together with neuro-
endocrine measures, this procedure is useful for obtaining
important information about the responsivity of the 5HT
system in OCD.
m-CPP (m-chlorophenylpiperazine) has been the most
frequently used probe to examine 5HT receptor function in
the studies of OCD. m-CPP is a non-selective agonist to
5HT1A, 5HT1D, 5HT2C receptor subtypes that antagonizes
stimulation of 5HT3 receptors (Gross et al 1998; McDougle
1999). It binds equipotently and with the greatest affinity to
5HT2C and 5HT3 receptor subtypes, and to a lesser extent
to 5HT1A and 5HT1D receptors (Gross et al 1998;
McDougle 1999). Zohar et al (1987) were the first to
examine the behavioral responses to m-CPP in OCD. Oral
m-CPP at the dose of 0.5 mg/kg, but not placebo, resulted
in a brief and significant exaggeration of OC symptoms in
11/12 (92%) OCD patients. Hollander et al (1992) confirmed
these results with a transient worsening of OC symptoms
in 11/20 (55%) OCD patients in similar experimental
conditions. Erzegovesi et al (2001) reported an increase in
OC symptom severity in 6/12 (50%) OCD patients with
0.25 mg/kg oral administration of m-CPP, whereas the usual
dose of 0.5 mg/kg caused an aggravation of OC symptoms
in only 1/12 (8%) OCD patients. Other authors found no
significant effect of oral m-CPP at the standard dose of
0.5 mg/kg on OC symptoms (Pigott et al 1993; Goodman et
al 1995; Ho Pian et al 1998a; Khanna et al 2001). Moreover,
there was also no exacerbation of OC symptoms after
intravenous challenge with m-CPP (0.1 mg/kg) (Charney et
al 1988), although a significant symptom aggravation was
more recently described (Pigott et al 1993; Broocks et al 1998).
The clinical heterogeneity of the patient populations studied
and differences in the rate of intravenous m-CPP infusion
might account for these discrepancies (McDougle 1999).
Concordant results have been reported regarding the
neuroendocrine effects of m-CPP in OCD. A blunted
response of cortisol (Zohar et al 1987; Khanna et al 2001)
or prolactin (Charney et al 1988; Hollander et al 1992;
Khanna et al 2001) to oral or intravenous m-CPP
administration was reported in OCD patients compared with
normal healthy volunteers.
Despite the disparate findings, the exaggerated
behavioral responses to m-CPP documented in some of the
previous studies support the hypothesis that OCD patients
may be hypersensitive at the level of the 5HT receptor
subtype in the brain regions involved in the production of
OC symptoms, among which the orbitofrontal and anterior
cingulate cortices or the caudate nucleus are the most often
cited (Saxena et al 1998; Baxter 1999; Aouizerate et al 2004).
This contrasts with the possible hyposensitivity of the 5HT
receptor subcategory present at the level of the hypo-
thalamic-pituitary-adrenal axis of OCD patients, as shown
by attenuated neuroendocrine responses to m-CPP. There
is evidence that the neuroendocrine properties of m-CPP
are related to direct agonist effects on postsynaptic 5HT
receptors by stimulation of 5HT1A and 5HT2C receptor
subtypes (Mueller et al 1986; Hamik and Peroutka 1989;
Cowen et al 1990). The actions of the drug are probably
mostly due to activation of 5HT2C receptors because of its
lower affinity to 5HT1A receptor subtype (Gross et al 1998;
McDougle 1999). Therefore, the observations of blunted
effects of m-CPP on cortisol or prolactin secretion are more
indicative of 5HT2C receptor dysfunction in the brain
regions that mediate hormonal responses. Platelet 5HT2
receptors have been studied in OCD (Pandey et al 1993).
The number and affinity of 5HT2 receptor binding sites did
not differ in OCD patients from those of normal healthy
volunteers, and there was no correlation with the clinical
severity of the illness. Thus, a disruption in 5HT2 receptor-
mediated signal transduction might occur, as supported by
enhanced platelet IP3 concentrations in OCD (Delorme et
al 2004).
These functional abnormalities of 5HT receptors appear
to be reversed in part by effective treatments of OCD. ZoharNeuropsychiatric Disease and Treatment 2005:1(3) 237
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et al (1988) reexamined the behavioral and hormonal effects
of oral m-CPP in OCD patients following four months of
successful treatment with clomipramine. m-CPP failed to
significantly increase OC symptoms. However, the hormonal
responses remained unchanged. Similar findings were
reported after at least 12 weeks of effective fluoxetine
treatment (Hollander et al 1991). The inability to normalize
neuroendocrine effects of m-CPP is presumably due to the
hyporesponsivity of postsynaptic 5HT2C receptors, which
would not be reversed by SRI administration.
MK-212 (6-chloro-2-[1-piperazinyl]-pyrazine) is a
direct-acting 5HT agonist that possesses high affinity for
5HT1A and 5HT2C receptor subtypes (Gross et al 1998).
Bastani et al (1990) assessed the behavioral and hormonal
responses to MK-212 (20 mg orally [os]) in OCD patients.
There was no change in the intensity of OC symptoms, while
attenuated cortisol and prolactin responses were observed.
Ipsapirone is an azapirone derivative with total
presynaptic 5HT1A receptor agonist activity and partial
agonist properties at postsynaptic 5HT1A receptor sites. It
is more selective for the 5HT1A receptor subtype compared
with buspirone, the prototypical agent in this class, which
also possesses a dopamine antagonistic activity (Barr et al
1992; McDougle 1999). Administered orally at the dose of
0.3 mg/kg in OCD patients, ipsapirone had no influence on
OC symptom intensity. Normal ACTH and cortisol
responses were found (Lesch et al 1991). Similarly, no
behavioral and neuroendocrine effects of buspirone (30 mg
os) were found (Lucey, Butcher, et al 1992; Norman et al
1994). Therefore, dysfunction of the 5HT1A receptor
subtype does not seem to be implicated in the patho-
physiology of OCD.
Fenfluramine exerts a complex action on the brain 5HT
system by inhibiting 5HT reuptake and facilitating
presynaptic 5HT release from storage granules. It also has
direct postsynaptic 5HT agonist effects. However, the d-
and l-isomers of fenfluramine have been shown to differ in
their activity profile. The d-isomer preponderantly interacts
with the 5HT system compared with the l-isomer, which
modulates dopamine function (Barr et al 1992; McDougle
1999). Fenfluramine challenges in OCD patients have
yielded relatively consistent findings. Racemic dl-
fenfluramine (60 mg os) had no effect on OC symptom
severity (Hollander et al 1992; McBride et al 1992), and
prolactin and cortisol responses were normal (Hollander et
al 1992, 1993; McBride et al 1992). However, lowered
prolactin (Lucey, O’Keane, et al 1992; Monteleone,
Catapano, Bortolotti, et al 1997) and cortisol responses
(Lucey, O’Keane, et al 1992; Monteleone, Catapano,
Tortorella, et al 1997) to d-fenfluramine have been found,
although only in female patients, with normalization
occurring after 10 weeks of effective treatment with
fluvoxamine (Monteleone, Catapano, Bortolotti, et al 1997).
L-tryptophan is the initial dietary 5HT precursor.
Because the enzyme tryptophan hydroxylase is not saturated
with substrate at physiologic concentrations, addition of
exogenous tryptophan stimulates 5HT synthesis (Barr et al
1992; Deutch and Roth 1999; Sanders-Bush and Mayer
2001). Studies of the behavioral and neuroendocrine effects
of the L-tryptophan in OCD have not been numerous. No
influence of the 5HT precursor (7 g intravenous [IV]) was
found on OC symptoms (Charney et al 1988), while the
prolactin response was significantly greater in OCD patients
compared with normal healthy controls (Charney et al 1988),
although the latter finding was not subsequently replicated
(Fineberg et al 1994).
Tryptophan depletion induced by drinking a tryptophan-
deficient amino acid mixture is an experimental procedure
that temporarily and markedly reduces blood tryptophan,
brain tryptophan, 5HT, and 5-HIAA in laboratory animals
with similar lowering in plasma available tryptophan in
humans (McDougle 1999; Van der Does 2001). When
applied in OCD patients, tryptophan depletion did not induce
any worsening of OC symptoms (Smeraldi et al 1996).
Moreover, no effect of tryptophan depletion was found on
OC symptom severity after successful treatment with various
SRIs, while a rapid return of depressed mood was observed
(Barr et al 1994). This suggests that acute depletion in 5HT
availability has no influence on OC symptoms. However,
reduction in brain 5HT that tryptophan depletion challenge
produces could be insufficient to aggravate OC
manifestations. Furthermore, the therapeutic effects of SRIs
in OCD, but not in depression, could not depend on the
short-term availability of 5HT (Barr et al 1994).
Methergoline is a non-selective antagonist to 5HT1/
5HT2 receptor subtypes that has been shown to block
physiological and hormonal responses to m-CPP in normal
healthy volunteers (Mueller et al 1986). No increase in OC
symptom severity was found following the oral adminis-
tration of methergoline (4 mg) in OCD patients (Zohar and
Insel 1987), but oral pretreatment with methergoline at the
same dose completely abolished the m-CPP-induced
exacerbation of OC symptoms (Pigott et al 1991, 1993).
However, OC symptoms emerged after administration of
methergoline to OCD patients who favorably responded to
treatment with clomipramine (2.5–24 months) (BenkelfatNeuropsychiatric Disease and Treatment 2005:1(3) 238
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et al 1989). These observations support the central role of
5HT neurotransmission in the m-CPP-elicited induction of
OC symptoms and their improvement by treatment with
SRIs.
The response of OCD patients to a series of 5HT
pharmacological challenges has been extensively studied.
Importantly, OC symptoms worsened with m-CPP, which
acts as an agonist to 5HT1A, 5HT1D, 5HT2C receptors and
as antagonist to the 5HT3 receptor. In contrast, MK-212,
which demonstrates an affinity for 5HT1A and 5HT2C
receptor subtypes, and the 5HT1A receptor agonists
ipsapirone or buspirone, have no effect on OC symptom
intensity. These observations support the hypothesis that
5HT1D and/or 5HT3 receptor subtypes may be involved in
the production of OC symptoms. In this respect, oral
sumatriptan, a selective 5HT1D receptor agonist, produced
a transient and significant aggravation of OC symptoms at
the dose of 100 mg (Gross et al 1998), a result confirmed in
more recent investigations (Stein et al 1999; Koran et al
2001). However, these provocative findings failed to be
replicated in other studies (Ho Pian, Westenberg, van Megan,
et al 1998; Boshuisen and den Boer 2000) using sumatriptan
or zolmitriptan, a recent selective 5HT1D receptor agonist,
which has better brain-penetrating properties than
sumatriptan. In addition, the 5HT3 receptor subtype does
not mediate m-CPP-induced worsening of OC symptoms.
Ondansetron, a potent 5HT3 antagonist, administered
alone (0.15 mg/kg IV) or in combination with m-CPP
(0.08 mg/kg IV) in OCD patients, failed to induce any
significant change in OC symptom severity (Broocks et al
1998). Therefore, a 5HT1D receptor hyperresponsivity
appears to be associated with the emergence of OC
manifestations. Such a dysfunction of the terminal 5HT1D
autoreceptor may be expected to reduce presynaptic release
and thus lead to decreased availability of extracellular 5HT.
Another example of evidence for the so-called “5HT1D
receptor hypothesis” (Zohar and Kindler 1992) is illustrated
by a family-based association study of the 5HT1Dβ receptor
gene (Mundo et al 2000, 2002). G and C alleles of this gene
differ by a single base pair at nucleotide 861 of the coding
region (Pato et al 2002). Significant linkage disequilibrium
between the G861C variant of the 5HT1Dβ receptor gene
and OCD was found, with preferential transmission of the
G allele to the affected subjects (Mundo et al 2000, 2002).
Although this association has not been confirmed (Di Bella
et al 2002; Camarena et al 2004), subjects with a preferential
transmission of the G allele experienced more severe OC
symptoms than those carrying the C allele (Camarena et al
2004). Thus, it can be concluded that there is a putative
involvement of the 5HT1Dβ receptor gene in the etio-
pathogenesis of OCD.
Perspectives
Abundant neurochemical data obtained with various
approaches suggest the central role of the 5HT system in
OCD. In this respect, we will first seek to establish strong
relationships with the anatomo-functional model of OCD
that has emerged due to the existence of functional
abnormalities in the frontal-subcortical loops, and second,
to define the importance of possible interactions with other
neurotransmitter systems, particularly dopamine, in the
genesis of OC symptomatology.
Toward a relationship with the
anatomo-functional model of OCD
Although the pathophysiology of OCD is still far from
resolved, functional neuroimaging studies have provided
important information about the brain regions involved in
OCD. A consensus is emerging regarding an enhanced
metabolic activity in several brain areas including the
orbitofrontal and anterior cingulate cortices, the ventral
striatum (head of the caudate nucleus) and the thalamus
(Saxena et al 1998; Baxter 1999; Aouizerate et al 2004),
and our knowledge of the physiology of the cortico-
subcortical functional loops involving these brain regions
in the expression of OC symptoms is increasing.
Phenomenologically, the central point of the obsessional
symptomatology is the subjective impression that
“something is wrong” (Schwartz 1998, 1999). In other
words, obsessions may be considered as resulting from the
recurrent perception of a mistake and/or error in response
to specific environmental stimuli. Compulsions are defined
as behavioral responses performed to alleviate the internal
tension or anxiety produced by exposure to the stimuli. This
relief may be thought as a form of reward. Nevertheless, it
is usually brief and immediately followed by a resurgence
of profound discomfort. This results in the urge to carry out
reward-directed behaviors in an unreasonable and excessive
way on the basis of an internal, emotional, and motivational
drive. These phenomenological aspects are of major
significance in terms of processes disrupted within OCD,
including: (1) error recognition; and (2) emotion and
motivation and their activational aspects (eg, activations for
initiation and sustaining behavioral reactions and tendency
to work for reward) (Aouizerate et al 2004). Therefore, itNeuropsychiatric Disease and Treatment 2005:1(3) 239
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can be assumed that a dysfunction of the brain regions
mediating the processes of error detection and/or
management of the reward and emotion occurs in OCD. In
this respect, it has been shown that the orbitofrontal cortex
(OFC) is involved in appraisal in determining the emotional
and motivational values of environmental information, and
in integrating the subject’s prior experience, which is crucial
in decision-making (Charney and Bremner 1999; Tremblay
and Schultz 1999, 2000a, 2000b; Krawczyk 2002; Ramnani
and Owen 2004). The OFC also contributes to the selection,
comparison and judgment of stimuli, and error detection
(Rosenkilde et al 1981; Thorpe et al 1983; Ramnani and
Owen 2004). The anterior cingulate cortex (ACC) is divided
into: (1) a ventral or affective region that could keep attention
on the internal emotional and motivational status and
participates in the regulation of autonomic responses; and
(2) a dorsal and cognitive region that serves a wide range of
functions such as attention, working memory, error
detection, conflict monitoring, response selection, and
anticipation of incoming information (Niki et Watanabe
1979; Devinsky et al 1995; Shima and Tanji 1998; Bush et
al 2000, 2002; Akkal et al 2002; Shidara and Richmond
2002; Ito et al 2003; Kerns et al 2004). The ventral striatum,
which is intimately connected to the OFC and ACC, is
primarily involved in the preparation, initiation, and
execution of behavioral responses oriented toward reward
delivery after cognitive and emotional integration of
behaviorally relevant information at the cortical level
(Hollerman et al 1998; Tremblay et al 1998; Hassani et al
2001). Thus, these observations indicate the crucial role of
the brain regions belonging to the orbitofrontal and anterior
cingulate loops in the pathophysiology of OCD in the light
of phenomenological evidence.
The responsibility of 5HT neurotransmission for the
dysfunction of the frontal-subcortical loops that emanate
from the OFC and ACC remains to be established (Figure 1).
However, there are several strands of indirect evidence
particularly implicating the 5HT1D receptor in the mediation
of these functional abnormalities. First, in various animal
species, there is an abundant 5HT innervation along with
an expression of the terminal autoreceptor 5HT1B (termed
5HT1D in humans) in the cortex, especially in the limbic
areas and related structures (eg, ventral striatum, amygdala,
hippocampus, and thalamus) (Boschert et al 1994; Glennon
and Dukat 1995; Stahl 1998; Meneses 1999). Second,
antidepressant drugs that predominantly inhibit 5HT
reuptake have largely proven effective for treating OCD
(Flament and Bisserbe 1997; Goodman 1999; McDougle
1999; Pigott and Seay 1999), resulting in a progressive
decline in the metabolic activity of the brain regions cited
above (Saxena et al 1998; Baxter 1999; Aouizerate et al
2004). Third, the anti-obsessional response of SRIs appears
to be related to a desensitization of the terminal 5HT
autoreceptor in the orbitofrontal cortex, disinhibiting
neuronal firing and then increasing 5HT tonus (Bergqvist
et al 1999). Fourth, pharmacological agents that conversely
reduce 5HT function by acting as agonists to the terminal
autoreceptor 5HT1D have been shown to aggravate the
severity of OC manifestations (Zohar et al 1987; Hollander
et al 1992; Pigott et al 1993; Broocks et al 1998; Erzegovesi
et al 2001), thus suggesting that the 5HT1D receptor subtype
may be hypersensitive in OCD. This is particularly important
for explaining the delayed onset of the optimal beneficial
effects of SRIs in OCD and the long-time course for this
desensitization of the terminal 5HT autoreceptor, which also
depends on the brain region (Stahl 1998). Preclinical studies
have found that the delay to obtain desensitization of the
5HT autoreceptor is longer in the orbitofrontal cortex than
in other cortical regions (El Mansari et al 1995). Thus,
although there is no direct conclusion of a clearly specific
5HT abnormality to date, a 5HT component particularly
involving the 5HT1D receptor subtype seems to exist in the
pathophysiology of OCD.
Toward a possible interaction with the
dopaminergic system in OCD
5HT function cannot be considered as solely implicated in
the pathogenesis of OCD. Among the putative neuro-
transmitter systems that are thought to play a major role in
the expression of OC symptoms, the dopamine system with
which 5HT interacts, probably represents the most likely
candidate. First, antidopaminergic agents have favorable
effects in the management of SRIs-resistant forms of OCD
with and without comorbid tics (McDougle et al 1994, 1995,
2000; Saxena et al 1996). Second, a disturbance in
dopaminergic function seems to be observed in OCD, as
supported by recent neuroimaging studies showing an
increase in dopamine transporter binding along with lowered
levels of dopaminergic D2 receptor binding in the basal
ganglia of patients with OCD (Kim et al 2003; Denys et al
2004). This might reflect a compensatory mechanism
resulting from higher synaptic concentrations of dopamine
in the striatum, leading to an elevation in the dopamine
transporter and to a down-regulation of the D2 receptor.
Third, many studies have underlined the fundamentalNeuropsychiatric Disease and Treatment 2005:1(3) 240
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importance of dopamine in reinforcement (Kiyatkin 1995;
Le Moal 1995; Piazza and Le Moal 1996, 1997; Koob and
Le Moal 1997; Schultz 1998, 2000, 2002; Horvitz 2000;
Vallone et al 2000; Nieoullon 2002; Salamone and Correa
2002). Mesocorticolimbic dopamine neurons originating in
the ventral tegmental area and projecting largely to the
nucleus accumbens with other limbic ventral striatal regions
and cortical areas, especially the OFC and ACC (Horvitz
2000; Vallone et al 2000; Nieoullon 2002), are essential for
the learning and motivational processes, two critical aspects
of behaviors oriented to reaching goals or obtaining rewards
(Salamone and Correa 2002). Dopamine neurons encode a
reward error-prediction rule and provide information about
the predictability of the reward, which is central in reward-
directed learning (Schultz 1998, 2000, 2002). They are
modeled as the “critic” that produces evaluative feedback
by observing the consequences of a given action on the
environment, and which generates error signal when
differences are perceived between predictions and reality
(Bar-Gad and Bergman 2001). Dopamine neurons are also
involved in the activational aspects of motivation (eg,
activation to obtain and effort in working for reward
delivery) (Salamone and Correa 2002). In other words,
overactivity of the mesocorticolimbic system might be
reflected by the occurrence of recurrent obsessions resulting
from excessive and inappropriate feedback error signals
upon exposure to behavior-inducing stimuli. It may also be
essential in the emergence of compulsive behaviors as
reinforcing behavioral approach intended to reduce distress
related to intrusive thoughts (Aouizerate et al 2004). Thus,
the existence of anatomical and functional 5HT-dopamine
interactions at both cortical and subcortical levels (Kapur
and Remington 1996) and the modulating influence of 5HT
on motor behavior and its flexibility (Lucki 1998; Clarke
et al 2004) suggest that 5HT might act through the
dopaminergic system in the production of OC symptoms.
However, the exact significance of such interactions between
5HT and dopamine functions remains to be more elucidated.
Conclusion
The widely demonstrated efficacy of SRIs for the treatment
of OCD suggests the important role of the 5HT system in
the pathogenesis of OCD. Clinical studies based on
pharmacological challenges designed to manipulate the
functional activity of the 5HT system and its receptor
subtypes have failed to establish firm conclusions about the
induction of OC symptoms by 5HT mechanisms. However,
the use of m-CPP and sumatriptan remains an important
issue as shown by the worsening of clinical symptoms that
these agents induce. Investigations into this issue might
throw light on the potential importance of the 5HT1D
receptor subtype underlying the symptomatic expression of
OCD. Further research into developing more selective
probes of the 5HT1D receptor subsystem would provide
more information about this 5HT receptor subcategory
associated with the production of OC symptoms and about
the pharmacological molecular bases of the putative 5HT1D
receptor subtype malfunction.
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